Recombinant Human Tumor Necrosis Factor (rHTNF) Engineering Service

Recombinant Human Tumor Necrosis Factor (rHTNF), or TNF-alpha, is a powerful cytokine with established applications in cancer therapy (e.g., isolated limb perfusion). Its production in Escherichia coli poses two critical challenges: inactivity in prokaryotic expression occurs because rHTNF naturally forms a trimer, and expression in the reducing E. coli cytoplasm often leads to misfolding and aggregation into inactive inclusion bodies. Furthermore, native rHTNF has high toxicity (e.g., systemic inflammation, septic shock-like syndrome) at therapeutic doses, severely limiting its clinical utility. Biosynthesis optimization allows for the generation of safer and more functional variants.

CD Biosynsis offers a synthetic biology service focused on engineering both the production system and the protein structure of rHTNF. Our core strategy involves modification of fusion expression system in Escherichia coli . We utilize highly soluble fusion tags (e.g., SUMO, Trx, MBP) to enhance the solubility and proper folding of rHTNF in the E. coli cytoplasm, promoting the correct trimer formation necessary for activity. The tag is removable post-purification. This is coupled with mutation of protein active sites . We employ site-directed mutagenesis to introduce specific mutations within the TNF-R1 or TNF-R2 receptor binding sites. The goal is to reduce systemic toxicity by selectively diminishing receptor binding (often TNF-R1 which mediates systemic toxicity) while preserving or enhancing anti-tumor activity (often mediated by TNF-R2 or local high concentration). This integrated approach aims to deliver high yields of a biologically active, stable, and less systemically toxic rHTNF variant.

Pain Points

Efficient and safe rHTNF production faces these key challenges:

• Inactivity in Prokaryotic Expression: The active form of rHTNF is a non-covalently linked trimer . Expressing it in E. coli often results in misfolded, inactive monomers or aggregates within insoluble inclusion bodies , requiring complex and costly refolding procedures.
• High Toxicity: Native rHTNF is a pleiotropic cytokine. Its signaling through the two main receptors (TNF-R1 and TNF-R2) is responsible for its beneficial (anti-tumor) and detrimental (systemic inflammation) effects. The systemic toxicity is often dose-limiting in clinical trials.
• Refolding Difficulty: The complex trimeric structure makes the protein highly susceptible to aggregation during the necessary refolding steps after purification from inclusion bodies.
• Short Half-life: Native rHTNF has a relatively short in vivo half-life, necessitating frequent, high-dose administration, which exacerbates the toxicity risk .

A successful solution requires overcoming the folding obstacle and engineering receptor-binding specificity for increased safety.

Solutions

CD Biosynsis utilizes advanced expression system and protein engineering to optimize active, safer rHTNF production in E. coli:

Modification of Fusion Expression System in E. coli

           

We employ a SUMO or MBP (Maltose-Binding Protein) fusion tag to significantly increase the solubility of rHTNF and promote correct trimerization in the E. coli cytoplasm.

Mutation of Protein Active Sites

We use structure-guided site-directed mutagenesis to introduce mutations that selectively reduce the binding affinity to TNF-R1 (toxicity mediator) while maintaining or enhancing the binding to TNF-R2 (therapeutic mediator).

Soluble Expression Strain Utilization

We utilize specialized E. coli strains (e.g., SHuffle or Origami) that favor the oxidizing environment necessary for disulfide bond formation, enhancing correct protein folding and activity.

PEGylation/Half-life Extension

We introduce a C-terminal cysteine residue or surface lysine residues to facilitate specific PEGylation for rHTNF variants, extending the in vivo half-life and allowing for less frequent dosing.

This systematic approach generates a readily soluble product and ensures that the engineered variant possesses a superior therapeutic index.

Advantages

Our rHTNF engineering service is dedicated to pursuing the following production goals:

High Yield of Active Trimer

Fusion tags significantly boost solubility and correct trimerization , eliminating the need for complex refolding and aggregation.

Reduced Systemic Toxicity

Active site mutations create variants with preferential anti-tumor activity and decreased systemic side effects.

Cost-Effective Production

Soluble expression in E. coli is highly scalable and avoids the high cost of mammalian expression systems and refolding protocols.

Enhanced Half-life

Potential PEGylation sites allow for further engineering to prolong circulation time , improving dosing frequency.

High Purity Monomer

The use of SUMO or MBP tags with specific proteases ensures the clean removal of the tag , resulting in high purity active rHTNF monomer.

We provide a specialized platform for developing next-generation, safer TNF-alpha therapeutics.

Process

Our rHTNF engineering service follows a rigorous, multi-stage research workflow:

• Gene Design and Mutagenesis: Synthesize the rHTNF gene, including codon optimization and introduction of toxicity-attenuating mutations based on TNF-R1/R2 structure data.
• Fusion Expression Vector Construction: Clone the gene into a vector optimized for E. coli soluble expression, utilizing a SUMO or MBP fusion tag followed by a specific protease cleavage site.
• Expression Optimization: Screen specialized E. coli host strains and optimize induction conditions (e.g., low temperature) to maximize the yield of soluble fusion protein .
• Purification and Cleavage: Isolate the fusion protein using affinity chromatography (e.g., Ni-NTA), cleave the fusion tag with a specific protease, and purify the active rHTNF trimer .
• Functional and Binding Assays: Verify trimeric formation via SEC-HPLC and confirm biological activity using cytotoxicity assays (e.g., L929 cell line). Conduct SPR or Octet to validate the desired receptor binding profile (reduced TNF-R1 affinity).
• Result Report Output: Compile a detailed Experimental Report including gene modification data, purification protocols, and functional data (activity titer, binding affinity) , supporting clinical development.

Technical communication is maintained throughout the process, focusing on timely feedback regarding solubility and binding specificity.

Explore the potential for a safer, more active rHTNF therapeutic. CD Biosynsis provides customized protein engineering solutions:

• Detailed Receptor Binding and Cytotoxicity Report , demonstrating the improved therapeutic index of the mutant variant.
• Consultation on optimized E. coli fermentation and downstream processing for soluble rHTNF purification.
• Experimental reports include complete raw data on final active rHTNF titer (mg/L) and trimerization efficiency (%) , essential for process feasibility.